Pear Therapeutics, Inc. (PEAR) Research

Pear Therapeutics, Inc. is a commercial-phase medical company focused on inventing and distributing digital therapeutics. Its current offerings include reSET, which addresses substance use disorders involving alcohol, cannabis, cocaine, and stimulants; reSET-O, prescribed alongside buprenorphine for opioid use disorder; and Somryst, a digital solution for chronic insomnia. Beyond these marketed therapies, the company maintains a robust development pipeline of 14 prospective products. These investigational treatments span various therapeutic areas, encompassing psychiatry, neurology, and non-central nervous system conditions like gastrointestinal, oncological, and cardiovascular disorders. Founded in 2013, Pear Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Market snapshot

Symbol
PEAR
Price
$0.03
Day change
0.00%
Market cap
$4.1M
P/E ratio
-0.17x
52-week range
0.009-6.74
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Analyst price target
$6.50

Peer companies

  • Aptose Biosciences Inc. (APTO)
  • Gamida Cell Ltd. (GMDA)
  • Gritstone bio, Inc. (GRTS)
  • Hillstream BioPharma, Inc. (HILS)
  • Xylo Technologies Ltd. (MDGS)
  • Nabriva Therapeutics plc (NBRVF)
  • Ra Medical Systems, Inc. (RMED)
  • TNF Pharmaceuticals, Inc. (TNFA)

Recent insider activity

  • 5AM Partners IV, LLC — S-Sale (3172769 shares) on 2023-04-10
  • 5AM Partners IV, LLC — S-Sale (534855 shares) on 2023-04-10
  • Snow Ellen — A-Award (199864 shares) on 2023-02-15
  • Snow Ellen — A-Award (40000 shares) on 2023-02-16
  • Brenner Erin K. — A-Award (952380 shares) on 2023-02-15

Open Pear Therapeutics, Inc. (PEAR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.